Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval
Lutetium Lu 177 dotatate FDA approval (NDA 208700), NETTER-1/2 trials, HCPCS A9513 billing, and nuclear medicine site-of-care requirements.